Navigation Links
Masimo to Present at William Blair & Company 31st Annual Growth Stock Conference
Date:6/3/2011

IRVINE, Calif., June 3, 2011 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the William Blair & Company 31st Annual Growth Stock Conference at the Four Seasons Hotel in Chicago on Wednesday, June 15, at 8:00 a.m. Central Time.  A live audiocast of the presentation will be available on the Masimo website at www.masimo.com.  A replay of the audiocast will be available following the live presentation.

About Masimo Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® Pulse CO-Oximetry, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2009, Masimo introduced rainbow Acoustic Monitoring, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.Investor Contact:Media Contact:Sheree Aronson

Dana BanksVice President, Investor Relations

Manager, Public RelationsMasimo Corporation

Masimo Corporation(949) 297-7043

(949) 297-7348saronson@masimo.com

dbanks@masimo.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.


'/>"/>

SOURCE Masimo
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
2. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
3. New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries
4. Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products
5. Masimo Radical-7(R) and Rad-57(R) Pulse CO-Oximeters(TM) Awarded Airworthiness Release Certification by the United States Army
6. Childrens Hospital Oakland Standardizes to Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Technology
7. Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
8. New Study Funded By the National Institutes of Health (NIH) Finds Masimo SpCO(R) May Provide a Noninvasive Measure of Acute Asthma Severity in Children
9. Masimo to Present at the Deutsche Bank 34th Annual Health Care Conference
10. Masimo to Report First Quarter 2009 Financial Results on May 5, 2009
11. New Clinical Study Shows Masimo PVI(TM) Accurately Predicts Fluid Responsiveness in the ICU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Ca (PRWEB) , ... August 16, 2017 , ... ... by changing into a different cell type. Many treatments for specific cancers, such ... prominent example of targeted treatment is androgen deprivation therapy for advanced prostate cancer. ...
(Date:8/16/2017)... Aug. 16, 2017  This year,s edition of the Inc. 5000 features ... sciences workforce solutions, has made the list for the third year in ... nation,s fastest-growing private companies based on a set of quantitative metrics. In ... the fastest-growing companies in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... CA (PRWEB) , ... August 15, 2017 , ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... number of steps needed to gain kinetic binding data for a wide range ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum ... Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The partnership ... 2018, at The Roosevelt Hotel in New York City. , “With our experience in ...
Breaking Biology Technology:
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):